Integra Therapeutics, a biotechnology company that is creating next-generation gene writing tools, announced today the appointment of Professor George Church to its Scientific Advisory Board (SAB).

“We are thrilled for Prof. George Church to join Integra Therapeutics’ SAB. His pioneering work in DNA sequencing methods and mammalian genome editing plus his experience co-founding several biotech companies will help us expand our  leadership position in the field of gene writing,” remarks Dr Avencia Sánchez-Mejías, co-founder and CEO of Integra  Therapeutics.

Prof. George Church is a pioneering scientist in reading and writing DNA. He developed the first direct genomic sequencing method and helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005 and demonstrated that CRISPR/Cas9 could be used to edit human stem cells—several in a very long list of contributions. Currently, he is professor of Genetics at Harvard Medical School and professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT). He also leads the Harvard Molecular Technologies lab in Boston. He has authored more than 600 papers, 155 patent publications and a book, Regenesis.

Integra Therapeutics is a biotechnology company that is creating next-generation gene writing  tools to make advanced therapies safer and more effective. The company was founded in 2020 as a spin-off of Pompeu Fabra University (UPF) by Dr Marc Güell and Dr Avencia Sánchez-Mejías and is based at the Barcelona Biomedical Research Park (PRBB). It is supported by international investors (AdBio Partners, Invivo Capital and Takeda Ventures) and organisations in the healthcare and biomedicine sector.

More  information

Photo: Prof. George Church – © Harvard